ITGAX and asthma: What remains unclear is if whole organ steady‐state pulmonary ceramide changes are necessary to drive the observed enhancement of the asthma‐like phenotype or whether alterations of sphingolipid metabolism in critical ceramide‐sensitive cellular subpopulations, such as Cd11c+ immune cells, are alone sufficient to drive the amplified pathology.